# OnCo record myeloproliferative-neoplasms (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/myeloproliferative-neoplasms/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "myeloproliferative-neoplasms" ;
  schema:name "Myeloproliferative neoplasms (PV, ET, myelofibrosis)"@en ;
  schema:alternateName "MPN"@en, "Polycythaemia vera"@en, "Essential thrombocythaemia"@en, "Primary myelofibrosis"@en ;
  schema:description "Myeloproliferative neoplasms are slow-growing blood cancers in which the marrow overproduces red cells (polycythaemia vera), platelets (essential thrombocythaemia) or scar tissue (myelofibrosis). Almost all carry a mutation in JAK2, CALR or MPL; treatment aims to prevent clots and control symptoms, and only transplant cures myelofibrosis."@en ;
  schema:url <https://onco.cc/cancers/myeloproliferative-neoplasms/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Myeloproliferative_neoplasm> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1898104> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1477>, <https://www.cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq>, <https://www.mpnresearchfoundation.org/> ;
  onco:tag "gap-fill", "haematologic" ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/cytokine-therapy/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/> ;
  onco:targets <https://onco.cc/targets/jak2/>, <https://onco.cc/targets/bcl2/> ;
  onco:drugs <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/fedratinib/>, <https://onco.cc/drugs/pacritinib/>, <https://onco.cc/drugs/momelotinib/>, <https://onco.cc/drugs/hydroxyurea/>, <https://onco.cc/drugs/ropeginterferon-alfa-2b/>, <https://onco.cc/drugs/rusfertide/>, <https://onco.cc/drugs/luspatercept/>, <https://onco.cc/drugs/anagrelide/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/gsk/>, <https://onco.cc/companies/incyte/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:terms <https://onco.cc/terms/eln-risk/> ;
  onco:trials <https://onco.cc/trials/nct06093672/>, <https://onco.cc/trials/nct06351631/>, <https://onco.cc/trials/nct04468984/>, <https://onco.cc/trials/nct06468033/>, <https://onco.cc/trials/nct04717414/>, <https://onco.cc/trials/nct04562389/>, <https://onco.cc/trials/verify/>, <https://onco.cc/trials/nct07429266/>, <https://onco.cc/trials/nct05481151/>, <https://onco.cc/trials/nct06033586/>, <https://onco.cc/trials/nct04064060/>, <https://onco.cc/trials/nct04576156/>, <https://onco.cc/trials/nct04285086/>, <https://onco.cc/trials/nct04655092/> ;
  onco:pipeline <https://onco.cc/drugs/rusfertide/>, <https://onco.cc/drugs/momelotinib/>, <https://onco.cc/drugs/luspatercept/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/givinostat/>, <https://onco.cc/drugs/bomedemstat/>, <https://onco.cc/drugs/navitoclax/>, <https://onco.cc/drugs/krt-232/>, <https://onco.cc/drugs/flonoltinib/>, <https://onco.cc/drugs/jbi-802/> ;
  onco:standardOfCare <https://onco.cc/drugs/hydroxyurea/>, <https://onco.cc/drugs/ropeginterferon-alfa-2b/>, <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/rusfertide/>, <https://onco.cc/drugs/hydroxyurea/>, <https://onco.cc/drugs/ropeginterferon-alfa-2b/>, <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/fedratinib/>, <https://onco.cc/drugs/pacritinib/>, <https://onco.cc/drugs/momelotinib/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/trials/comfort-i/>, <https://onco.cc/trials/comfort-ii/>, <https://onco.cc/drugs/momelotinib/>, <https://onco.cc/drugs/luspatercept/> .